SCHEMBL20203462

SCHEMBL20203462

CSc1ncc2cc(CCOC(=O)c3ccccc3)nc(N3CCCCC3)c2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
TP53 P04637 3/20 0.39
LMNA P02545 2/20 0.39
PKM P14618 3/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
MAPK1 P28482 2/20 0.37
ALDH1A1 P00352 4/20 0.36
TSHR P16473 2/20 0.36
HPGD P15428 1/20 0.36
SCN1A P35498 1/20 0.36
SCN2A Q99250 1/20 0.36
SCN3A Q9NY46 1/20 0.36
NPSR1 Q6W5P4 1/20 0.35
TDP1 Q9NUW8 2/20 0.35
POLB P06746 1/20 0.35
METAP1 P53582 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
NPY5R Q15761 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20203438 0.91 MEN1 (0.48) MEN1KMT2ATP53LMNAALDH1A1
SCHEMBL20203487 0.84 LMNA (0.38) TP53LMNAPKMMAPK1ALDH1A1
SCHEMBL20203574 0.83 PKM (0.44) MEN1KMT2ALMNAPKMCYP2C9
SCHEMBL21403165 0.82 PDE4B (0.42) MEN1KMT2ATP53ALDH1A1POLB
SCHEMBL20203540 0.79 KMT2A (0.42) MEN1KMT2ATP53LMNAALDH1A1
SCHEMBL20203513 0.79 KMT2A (0.42) MEN1KMT2ATP53LMNAALDH1A1
SCHEMBL20203385 0.77 MEN1 (0.46) MEN1KMT2ALMNACYP2C9CYP2C19
SCHEMBL20203486 0.77 TP53 (0.40) TP53LMNAPKMMAPK1ALDH1A1
SCHEMBL20203522 0.74 MEN1 (0.47) MEN1KMT2ATP53LMNACYP2C9
SCHEMBL28942023 0.74 KMT2A (0.47) KMT2ATP53ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11084814-B2 Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof TEIJIN PHARMA LIMITED (JP) 2021-08-10 US disclosed
WO-2018097297-A1 PYRIDO[3, 4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF 帝人ファーマ株式会社 2018-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11084814-B2 Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof CDK4, CDK6, CDK16 MEN1 2438/4885KMT2A 657/4885TP53 176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.